 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
regulation of apoptosis
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
280:4738-4744
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands.
|
|
C.L.Day,
L.Chen,
S.J.Richardson,
P.J.Harrison,
D.C.Huang,
M.G.Hinds.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The B cell lymphoma-2 (Bcl-2) homologs myeloid cell leukemia-1 (Mcl-1) and A1
are prosurvival factors that selectively bind a subset of proapoptotic Bcl
homology (BH) 3-only proteins. To investigate the molecular basis of the
selectivity, we determined the solution structure of the C-terminal Bcl-2-like
domain of Mcl-1. This domain shares features expected of a prosurvival Bcl-2
protein, having a helical fold centered on a core hydrophobic helix and a
surface-exposed hydrophobic groove for binding its cognate partners. A number of
residues in the binding groove differentiate Mcl-1 from its homologs, and in
contrast to other Bcl-2 homologs, Mcl-1 has a binding groove in a conformation
intermediate between the open structures characterized by peptide complexes and
the closed state observed in unliganded structures. Mutagenesis of potential
binding site residues was used to probe the contributions of groove residues to
the binding properties of Mcl-1. Although mutations in Mcl-1 had little impact
on binding, a single mutation in the BH3-only ligand Bad enabled it to bind both
Mcl-1 and A1 while retaining its binding to Bcl-2, Bcl-xL, and Bcl-w.
Elucidating the selective action of certain BH3-only ligands is required for
delineating their mode of action and will aid the search for effective
BH3-mimetic drugs.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
FIG. 2. The BH3 binding activity is located in the Bcl-2
homology domain, and the C-terminal residues of this domain
modulate ligand binding. A, immunoprecipitation of Mcl-1
variants from 293T cells. Equivalent 35S-labeled cell lysates
from cells expressing FLAG-Mcl-1 variants and EE-Bim[EL] were
immunoprecipitated using anti-FLAG M2 ( -F), anti-EE ( -E), or
control anti-HA ( -H) monoclonal
antibodies and fractionated on SDS-PAGE gels (left column).
Western blots (middle and right columns) were performed with
anti-Bim and anti-FLAG 9H1 antibodies. Mcl-1 degradation product
is indicated by *. B, kinetic data for binding of BimBH3 peptide
to Mcl-1 NC23 and Mcl-1 NC11.
BimBH3 peptide was immobilized. C, Mcl-1 NC23 and Mcl-1 NC11
bind to the same proapoptotic proteins. The ability of the Mcl-1
proteins to bind to proapoptotic proteins was tested using GST
pulldown experiments. Equivalent amounts of the GST fusion
proteins were used in each experiment. Bound Mcl-1 was detected
by Coomassie staining
|
 |
Figure 4.
FIG. 4. Comparison of Mcl-1 and Bcl-x[L] binding grooves.
A, Bcl-x[L] and Mcl-1 binding sites. Left and middle, unliganded
Bcl-x[L] (PDB 1PQ0 [PDB]
) (39) and Bcl-x[L]-Bim complex with the Bim ligand removed (PDB
1PQ1 [PDB]
) (39) (respectively, ribbon residues: 90-159 and 191-196).
Right, the equivalent residues (194-264 and 296-301) on Mcl-1.
The orientation is the same as Fig. 3. Side chains displayed on
Bcl-x[L]-Bim (middle) are those of residues that have atoms
within 4 Å of a Bim atom on Bcl-x[L], and the analogous
side chains are displayed on the other structures. The side
chains are colored according to their proximity to a BH3-only
residue (panel B). Pink represents residues close to the
conserved Asp; those residues close to the conserved Leu of the
BH3 domain are magenta. Cyan-, yellow-, and orange-colored
residues surround the 3 hydrophobic residues at heptad positions
2d, 3d, and 4a, respectively (panel B). Other proximal residues
are highlighted in blue. Bcl-x[L] Phe-97 has atoms within 4
Å of Ile-97 and Phe-101 of Bim. B, sequences of BH3
domains of mouse BH3-only proteins. The color scheme indicates
key interactions consistent with those in panel A. Residues
underlined in Bim and Bad are those that are helical in their
Bcl-x[L] complexes (34, 39). The heptads are indicated.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2005,
280,
4738-4744)
copyright 2005.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
D.M.Hockenbery
(2010).
Targeting mitochondria for cancer therapy.
|
| |
Environ Mol Mutagen, 51,
476-489.
|
 |
|
|
|
|
 |
D.P.Stewart,
B.Koss,
M.Bathina,
R.M.Perciavalle,
K.Bisanz,
and
J.T.Opferman
(2010).
Ubiquitin-independent degradation of antiapoptotic MCL-1.
|
| |
Mol Cell Biol, 30,
3099-3110.
|
 |
|
|
|
|
 |
D.S.Dalafave,
and
G.Prisco
(2010).
Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics.
|
| |
Cancer Inform, 9,
169-177.
|
 |
|
|
|
|
 |
E.Fire,
S.V.Gullá,
R.A.Grant,
and
A.E.Keating
(2010).
Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes.
|
| |
Protein Sci, 19,
507-519.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.J.Rautureau,
C.L.Day,
and
M.G.Hinds
(2010).
Intrinsically disordered proteins in bcl-2 regulated apoptosis.
|
| |
Int J Mol Sci, 11,
1808-1824.
|
 |
|
|
|
|
 |
L.Prochazka,
L.F.Dong,
K.Valis,
R.Freeman,
S.J.Ralph,
J.Turanek,
and
J.Neuzil
(2010).
alpha-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels.
|
| |
Apoptosis, 15,
782-794.
|
 |
|
|
|
|
 |
Y.Guillemin,
J.Lopez,
D.Gimenez,
G.Fuertes,
J.G.Valero,
L.Blum,
P.Gonzalo,
J.Salgado,
A.Girard-Egrot,
and
A.Aouacheria
(2010).
Active fragments from pro- and antiapoptotic BCL-2 proteins have distinct membrane behavior reflecting their functional divergence.
|
| |
PLoS One, 5,
e9066.
|
 |
|
|
|
|
 |
E.F.Lee,
P.E.Czabotar,
H.Yang,
B.E.Sleebs,
G.Lessene,
P.M.Colman,
B.J.Smith,
and
W.D.Fairlie
(2009).
Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.
|
| |
J Biol Chem, 284,
30508-30517.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Orzáez,
A.Gortat,
L.Mondragón,
and
E.Pérez-Payá
(2009).
Peptides and peptide mimics as modulators of apoptotic pathways.
|
| |
ChemMedChem, 4,
146-160.
|
 |
|
|
|
|
 |
N.S.Chari,
N.L.Pinaire,
L.Thorpe,
L.J.Medeiros,
M.J.Routbort,
and
T.J.McDonnell
(2009).
The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death.
|
| |
Apoptosis, 14,
336-347.
|
 |
|
|
|
|
 |
S.Oda,
M.Schröder,
and
A.R.Khan
(2009).
Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7.
|
| |
Structure, 17,
1528-1537.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Smits,
P.E.Czabotar,
M.G.Hinds,
and
C.L.Day
(2008).
Structural plasticity underpins promiscuous binding of the prosurvival protein A1.
|
| |
Structure, 16,
818-829.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.Lama,
and
R.Sankararamakrishnan
(2008).
Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations.
|
| |
Proteins, 73,
492-514.
|
 |
|
|
|
|
 |
D.Trachootham,
H.Zhang,
W.Zhang,
L.Feng,
M.Du,
Y.Zhou,
Z.Chen,
H.Pelicano,
W.Plunkett,
W.G.Wierda,
M.J.Keating,
and
P.Huang
(2008).
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
|
| |
Blood, 112,
1912-1922.
|
 |
|
|
|
|
 |
G.Lessene,
P.E.Czabotar,
and
P.M.Colman
(2008).
BCL-2 family antagonists for cancer therapy.
|
| |
Nat Rev Drug Discov, 7,
989.
|
 |
|
|
|
|
 |
L.P.Billen,
A.Shamas-Din,
and
D.W.Andrews
(2008).
Bid: a Bax-like BH3 protein.
|
| |
Oncogene, 27,
S93-104.
|
 |
|
|
|
|
 |
R.J.Youle,
and
A.Strasser
(2008).
The BCL-2 protein family: opposing activities that mediate cell death.
|
| |
Nat Rev Mol Cell Biol, 9,
47-59.
|
 |
|
|
|
|
 |
A.L.Pauleau,
N.Larochette,
F.Giordanetto,
S.R.Scholz,
D.Poncet,
N.Zamzami,
V.S.Goldmacher,
and
G.Kroemer
(2007).
Structure-function analysis of the interaction between Bax and the cytomegalovirus-encoded protein vMIA.
|
| |
Oncogene, 26,
7067-7080.
|
 |
|
|
|
|
 |
C.Aisenbrey,
U.S.Sudheendra,
H.Ridley,
P.Bertani,
A.Marquette,
S.Nedelkina,
J.H.Lakey,
and
B.Bechinger
(2007).
Helix orientations in membrane-associated Bcl-X(L) determined by 15N-solid-state NMR spectroscopy.
|
| |
Eur Biophys J, 37,
71-80.
|
 |
|
|
|
|
 |
C.Xing,
L.Wang,
X.Tang,
and
Y.Y.Sham
(2007).
Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.
|
| |
Bioorg Med Chem, 15,
2167-2176.
|
 |
|
|
|
|
 |
G.Tang,
C.Y.Yang,
Z.Nikolovska-Coleska,
J.Guo,
S.Qiu,
R.Wang,
W.Gao,
G.Wang,
J.Stuckey,
K.Krajewski,
S.Jiang,
P.P.Roller,
and
S.Wang
(2007).
Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
|
| |
J Med Chem, 50,
1723-1726.
|
 |
|
|
|
|
 |
J.L.Mott,
and
G.J.Gores
(2007).
Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death.
|
| |
Hepatology, 46,
906-911.
|
 |
|
|
|
|
 |
M.Aoyagi,
D.Zhai,
C.Jin,
A.E.Aleshin,
B.Stec,
J.C.Reed,
and
R.C.Liddington
(2007).
Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein.
|
| |
Protein Sci, 16,
118-124.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.G.Hinds,
C.Smits,
R.Fredericks-Short,
J.M.Risk,
M.Bailey,
D.C.Huang,
and
C.L.Day
(2007).
Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets.
|
| |
Cell Death Differ, 14,
128-136.
|
 |
|
|
|
|
 |
M.Kvansakul,
M.F.van Delft,
E.F.Lee,
J.M.Gulbis,
W.D.Fairlie,
D.C.Huang,
and
P.M.Colman
(2007).
A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak.
|
| |
Mol Cell, 25,
933-942.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Nguyen,
R.C.Marcellus,
A.Roulston,
M.Watson,
L.Serfass,
S.R.Murthy Madiraju,
D.Goulet,
J.Viallet,
L.Bélec,
X.Billot,
S.Acoca,
E.Purisima,
A.Wiegmans,
L.Cluse,
R.W.Johnstone,
P.Beauparlant,
and
G.C.Shore
(2007).
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
|
| |
Proc Natl Acad Sci U S A, 104,
19512-19517.
|
 |
|
|
|
|
 |
P.E.Czabotar,
E.F.Lee,
M.F.van Delft,
C.L.Day,
B.J.Smith,
D.C.Huang,
W.D.Fairlie,
M.G.Hinds,
and
P.M.Colman
(2007).
Structural insights into the degradation of Mcl-1 induced by BH3 domains.
|
| |
Proc Natl Acad Sci U S A, 104,
6217-6222.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.T.Uren,
G.Dewson,
L.Chen,
S.C.Coyne,
D.C.Huang,
J.M.Adams,
and
R.M.Kluck
(2007).
Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak.
|
| |
J Cell Biol, 177,
277-287.
|
 |
|
|
|
|
 |
S.Cooray,
M.W.Bahar,
N.G.Abrescia,
C.E.McVey,
N.W.Bartlett,
R.A.Chen,
D.I.Stuart,
J.M.Grimes,
and
G.L.Smith
(2007).
Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein.
|
| |
J Gen Virol, 88,
1656-1666.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.J.Malia,
and
G.Wagner
(2007).
NMR structural investigation of the mitochondrial outer membrane protein VDAC and its interaction with antiapoptotic Bcl-xL.
|
| |
Biochemistry, 46,
514-525.
|
 |
|
|
|
|
 |
X.Fu,
J.R.Apgar,
and
A.E.Keating
(2007).
Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL.
|
| |
J Mol Biol, 371,
1099-1117.
|
 |
|
|
|
|
 |
D.Zhai,
C.Jin,
A.C.Satterthwait,
and
J.C.Reed
(2006).
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins.
|
| |
Cell Death Differ, 13,
1419-1421.
|
 |
|
|
|
|
 |
J.Peng,
C.Tan,
G.J.Roberts,
O.Nikolaeva,
Z.Zhang,
S.M.Lapolla,
S.Primorac,
D.W.Andrews,
and
J.Lin
(2006).
tBid elicits a conformational alteration in membrane-bound Bcl-2 such that it inhibits Bax pore formation.
|
| |
J Biol Chem, 281,
35802-35811.
|
 |
|
|
|
|
 |
J.Zhuang,
and
H.J.Brady
(2006).
Emerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis.
|
| |
Cell Death Differ, 13,
1263-1267.
|
 |
|
|
|
|
 |
L.D.Walensky
(2006).
BCL-2 in the crosshairs: tipping the balance of life and death.
|
| |
Cell Death Differ, 13,
1339-1350.
|
 |
|
|
|
|
 |
L.D.Walensky,
K.Pitter,
J.Morash,
K.J.Oh,
S.Barbuto,
J.Fisher,
E.Smith,
G.L.Verdine,
and
S.J.Korsmeyer
(2006).
A stapled BID BH3 helix directly binds and activates BAX.
|
| |
Mol Cell, 24,
199-210.
|
 |
|
|
|
|
 |
M.F.van Delft,
and
D.C.Huang
(2006).
How the Bcl-2 family of proteins interact to regulate apoptosis.
|
| |
Cell Res, 16,
203-213.
|
 |
|
|
|
|
 |
P.S.Schwartz,
and
D.M.Hockenbery
(2006).
Bcl-2-related survival proteins.
|
| |
Cell Death Differ, 13,
1250-1255.
|
 |
|
|
|
|
 |
R.L.Rich,
and
D.G.Myszka
(2006).
Survey of the year 2005 commercial optical biosensor literature.
|
| |
J Mol Recognit, 19,
478-534.
|
 |
|
|
|
|
 |
J.Loh,
Q.Huang,
A.M.Petros,
D.Nettesheim,
L.F.van Dyk,
L.Labrada,
S.H.Speck,
B.Levine,
E.T.Olejniczak,
and
H.W.Virgin
(2005).
A surface groove essential for viral Bcl-2 function during chronic infection in vivo.
|
| |
PLoS Pathog, 1,
e10.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.M.Adams,
D.C.Huang,
A.Strasser,
S.Willis,
L.Chen,
A.Wei,
M.van Delft,
J.I.Fletcher,
H.Puthalakath,
J.Kuroda,
E.M.Michalak,
P.N.Kelly,
P.Bouillet,
A.Villunger,
L.O'Reilly,
M.L.Bath,
D.P.Smith,
A.Egle,
A.W.Harris,
M.Hinds,
P.Colman,
and
S.Cory
(2005).
Subversion of the Bcl-2 life/death switch in cancer development and therapy.
|
| |
Cold Spring Harb Symp Quant Biol, 70,
469-477.
|
 |
|
|
|
|
 |
S.N.Willis,
and
J.M.Adams
(2005).
Life in the balance: how BH3-only proteins induce apoptosis.
|
| |
Curr Opin Cell Biol, 17,
617-625.
|
 |
|
|
|
|
 |
S.N.Willis,
L.Chen,
G.Dewson,
A.Wei,
E.Naik,
J.I.Fletcher,
J.M.Adams,
and
D.C.Huang
(2005).
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.
|
| |
Genes Dev, 19,
1294-1305.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|